Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Selby

Showing results (281-290 of 316) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2011
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralizationElizabeth J Ilett, Montserrat Bárcena, Fiona Errington-Mais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Tumor infection by oncolytic reovirus primes adaptive antitumor immunityRobin J Prestwich, Fiona Errington, Elizabeth J Ilett, et al.
Oncoimmunology|January 4, 2018
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor modelsKatherine E Lewis, Mark J Selby, Gregg Masters, et al.
British Journal of Cancer|January 1, 1997
Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancerG Velikova, R E Banks, A Gearing, et al.
Molecular Therapy Oncolytics|October 9, 2018
APOBEC3 Mediates Resistance to Oncolytic Viral TherapyAmanda L Huff, Phonphimon Wongthida, Timothy Kottke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Leukemia|March 28, 2015
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemiaC Parrish, G B Scott, G Migneco, et al.
Cancer Immunology Research|May 30, 2014
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primatesChangyu Wang, Kent B Thudium, Minhua Han, et al.
Hematological Oncology|October 12, 2000
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvestsF E Davies, A C Rawstron, G Pratt, et al.
Pageof 32

Showing results (281-290 of 316) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2011
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralizationElizabeth J Ilett, Montserrat Bárcena, Fiona Errington-Mais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Tumor infection by oncolytic reovirus primes adaptive antitumor immunityRobin J Prestwich, Fiona Errington, Elizabeth J Ilett, et al.
Oncoimmunology|January 4, 2018
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor modelsKatherine E Lewis, Mark J Selby, Gregg Masters, et al.
British Journal of Cancer|January 1, 1997
Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancerG Velikova, R E Banks, A Gearing, et al.
Molecular Therapy Oncolytics|October 9, 2018
APOBEC3 Mediates Resistance to Oncolytic Viral TherapyAmanda L Huff, Phonphimon Wongthida, Timothy Kottke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Leukemia|March 28, 2015
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemiaC Parrish, G B Scott, G Migneco, et al.
Cancer Immunology Research|May 30, 2014
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primatesChangyu Wang, Kent B Thudium, Minhua Han, et al.
Hematological Oncology|October 12, 2000
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvestsF E Davies, A C Rawstron, G Pratt, et al.
Pageof 32